Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cancer\*
• •* Stage IC-IV disease
• •* Peritoneal carcinomatosis\* (ovarian-type) must not be a mucin-secreting tumor
• •* Stage IC patients must have malignant cells in ascitic fluid or peritoneal washings, tumor on the surface of the ovary, or preoperative capsule rupture NOTE: \* Histologic confirmation of a primary source in the ovary is not required.
• •If biospy is not available, cytology showing an adenocarcinoma is allowed provided the following criteria is met:
• •* Patient has a pelvis (ovarian) mass AND all of the following:
• •* Omental cake or other metastasis is larger than 2 cm in the upper abdomen and/or regional lymph node metastasis irrespective of size OR stage IV disease
• •* Serum CA 125/CEA ratio \> 25 or barium enema (or colonoscopy) and gastroscopy (or radiological examination of the stomach) are negative for the presence of a primary tumor and normal mammography within 6 weeks prior to study randomization
• •Initial cytoreductive laparotomy or biopsy required within the past 8 weeks
• •* Cytoreductive surgery may or may not have been successful during staging laparotomy
• •No mixed mesodermal tumors
• •No borderline ovarian tumors or tumors termed "possibly malignant"
• •No adenocarcinoma of unknown origin, if histologically confirmed to be a mucin-secreting tumor
• •Considered unsuitable for or unwilling to receive platinum-taxane combination therapy
• •No concurrent endometrial cancer
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •ECOG 0-3
• •Life expectancy
• •Not specified
• •Hematopoietic
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Hepatic
• •Bilirubin normal
• •AST and ALT ≤ 2.5 times upper limit of normal (ULN)
• •Alkaline phosphatase ≤ 5 times ULN
• •Renal
• •Creatinine clearance ≥ 30 mL/min
• •* Obstructive hydronephrosis as a cause of borderline (i.e., creatinine clearance 30-45 mL/min) renal function must be treated before study entry
• •Cardiovascular
• •No hypertension
• •No ischemic heart disease
• •No myocardial infarction within the past 6 months
• •No congestive heart failure
• •Other
• •Not pregnant or nursing
• •Fertile patients must use effective contraception
• •No symptomatic peripheral neuropathy ≥ grade 2
• •No uncontrolled infection
• •No other severe and/or uncontrolled medical condition
• •No other malignancy within the past 5 years except curatively treated carcinoma in situ of the cervix or basal cell skin cancer
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •No prior chemotherapy
• •No other concurrent cytotoxic chemotherapy until progressive disease occurs
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •No prior radiotherapy
• •Surgery
• •See Disease Characteristics